Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: Pliva


In the News (Sun 27 Dec 09)

  
  PLIVA.com - Company Details
PLIVA is the European generic pharmaceutical subsidiary of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.
PLIVA is also an emerging participant in the generic biopharmaceutical arena.
PLIVA’s strength lies in the Company’s diversity, professional staff and commitment to providing high-quality products through superior science, low-cost manufacturing and customer service.
www.pliva.com /en/about/details   (67 words)

  
 PLIVA.com - Home
PLIVA to announce Q2 2007 Financial Results on 10 August 2007
PLIVA in the UK: Humanitarian Donation of Medicines to Lebanon
PLIVA in Poland: PLIVA Kraków awarded for investments in R&D
www.pliva.com   (162 words)

  
 Vísir - Viðskipti - Viðskipti innlent
Actavis hefur selt allt hlutafé sitt í króatíska lyfjafyrirtækinu Pliva til bandaríska lyfjafyrirtækisins Barr.
Actavis átti 20,8 prósent hlutafjár í Pliva með beinum og óbeinum hætti en söluverðmæti nemur 820 kúnum á hlut.
Þá er haft eftir Róbert Wessman, forstjóra Actavis, að ákvörðun um sölu bréfa í Pliva sé í samræmi við fjárfestingastefnu félagsins.
www.visir.is /apps/pbcs.dll/article?AID=/20061020/VIDSKIPTI06/61020072/1091/FRETTIR01   (382 words)

  
 Barr takeover of Pliva appears certain - Boston.com
Pliva, created 80 years ago, reached its peak a decade or two ago, when it began purchasing smaller pharmaceuticals companies in southeast Europe and invented its own antibiotic.
The government, which controlled 18 percent of Pliva shares, is also believed to be among the sellers.
Many Croats still consider Pliva a "national treasure" and have opposed its sale, even though it was privatized in early 1990s, with the government keeping the 18 percent stake.
www.boston.com /business/healthcare/articles/2006/10/11/barr_acquires_70_pct_of_pliva_shares   (645 words)

  
 PLIVA Ljubljana : O NAS : V svetu :
PLIVA has focused its expertise on NCE research, and through this "Smart Discovery Strategy" globally competitive results are expected.
PLIVA's vision in research is to develop new drugs whose production will serve unmet medical needs and will have commercial returns in line with PLIVA's growth targets.
PLIVA's Competitive Generic Strategy is based on decades of experience and expertise in new API development coupled with regular and successful FDA inspections as well as PLIVA's excellence in chemistry and the innovative improvement of existing drugs.
www.pliva.si /multi2.php?p=1&menu_num=190   (305 words)

  
 PLIVA News   (Site not responding. Last check: 2007-10-25)
PLIVA also notes that following the withdrawal of this offer, the only remaining offer currently available for acceptance by shareholders will be that made by Barr Laboratories Europe B.V. at a price of HRK 820 per share, which is expected to expire on 11 October 2006.
PLIVA is the second largest investor in the Polish pharmaceutical industry in terms of the volume of outlays, and one of the biggest manufacturers of generic drugs in Poland.
PLIVA was the first pharmaceutical manufacturer in Poland to obtain the MHRA certificate in 2003.
www.pliva.ba /en/aktualnosti1.htm   (3420 words)

  
 Pliva
Pliva Fine Chemicals has a long standing presence in the API industry.
With a new emphasis being placed on specialty generics, Pliva is positioned to be a leader in API production for years to come.
Pliva has several FDA inspected facilities with a total capacity of over 800 cubic meters.
www.vinchem.com /Pliva.htm   (86 words)

  
 Pliva Research Facility [EBRD - Project Summary Document]
This loan will facilitate the construction of Pliva d.d.’s new state-of-the-art research institute in Zagreb for the development of new pharmaceutical substances.
The project will strengthen Pliva's research and development capacity, particularly in the field of macrolides, and will assist the company in becoming an important regional player in the pharmaceutical industry.
Pliva performed very well from the environmental perspective on the Bank's first financing.
www.ebrd.com /projects/psd/psd2000/12351.htm   (433 words)

  
 SignOnSanDiego.com > News > Business > Biotechnology -- U.S.'s Barr hopes to complete Pliva deal by October
Pliva, the biggest east European drug maker by sales, said on Tuesday it was backing Barr's offer of 705 kuna ($122.1) per share, with shareholders also entitled to the dividend of 12 kuna per share announced with its 2005 results.
Pliva GDRs, issued at five to a share in London, firmed 0.70 percent to $24.64 on Thursday amid market speculation that Actavis could still launch a higher counterbid for Pliva.
Pliva sees generic business, including strong input of biotechnology, as its main future earnings driver after a failed proprietary venture in the United States which, according to some estimates, incurred losses of more than $250 million.
www.signonsandiego.com /news/business/biotech/20060629-0448-health-pliva-barr.html   (527 words)

  
 Datamonitor - Barr linked to $2.1 billion bid for Pliva - News   (Site not responding. Last check: 2007-10-25)
Barr is likely to face competition for the capture of Pliva, eastern Europe's biggest drug maker, as the entire generics industry heads towards greater consolidation.
Pliva on the other-hand has so far refused to make any official comment on the new bid.
According to Financial Times reports, Pliva favors the Barr bid because it "would leave the management team largely in place".
www.datamonitor.com /~db936a0a65f0404aa62bb622497ef489~/companies/company/?pid=99D2FE24-BD90-41CD-B08E-3EBB83CB971A&nid=4377FC50-1ADD-4290-9B0F-CD8980FFBD78&type=NewsWire&article=1   (247 words)

  
 Da li je Pliva otplivala, isplivala ili potonula? at Mračni blog
Da li je Pliva otplivala, isplivala ili potonula?
4 Responses to “Da li je Pliva otplivala, isplivala ili potonula?”
Mračni blog is proudly powered by WordPress using the RockinBlue theme created by Cory Miller.
mrak.org /2006/06/30/pliva-otplivala-isplivala-potonula   (766 words)

  
 Pliva drops its German plant
Croatian drug firm Pliva has sold its Dresden production plant to Italy’s Menarini Group as it tries to recover losses suffered by its failed venture in proprietor drugs and an end to most of the royalties it receives.
But Pliva warned that restructuring charges of $22 million (€18.2 million), mainly related to asset impairment, will still mar its Q4 results.
The seller of the plant, AWD pharma, a Pliva subsidiary, was the target of much speculation last September, with rumours that it could be bought by Indian drugmaker Wockhardt.
www.in-pharmatechnologist.com /news/ng.asp?n=65612-pliva-menarini-group-berlin-chemie   (622 words)

  
 SignOnSanDiego.com > News > Business -- Barr acquires Pliva, agrees antitrust conditions
Barr also is required to divest either Pliva's or Barr's generic nimodipine for use in treating ruptured blood vessels in the brain, the FTC said.
Barr said Friday it had acquired 92 percent of Pliva's shares in response to its 820 kuna per share offer and plans a secondary listing in Zagreb.
Pliva operates in more than 30 countries, with its main markets in Europe and North America.
www.signonsandiego.com /news/business/20061020-1029-health-croatia-pliva-barr.html   (459 words)

  
 Datamonitor - Pliva and Mayne enter biogenerics pact - News   (Site not responding. Last check: 2007-10-25)
Pliva will retain full rights for CEE (including the 10 EU accession countries), the Americas, and Japan where it can market the products itself or with business partners.
Pliva will also be the exclusive supplier of these products to Mayne through a mutually attractive pricing arrangement which is adjusted according to the level of sales volumes and margins achieved.
Following extensive clinical trials in Croatia, Pliva has already submitted a generic EPO for registration in Croatia that is planned for launch this year.
www.datamonitor.com /~db936a0a65f0404aa62bb622497ef489~/companies/company/?pid=99D2FE24-BD90-41CD-B08E-3EBB83CB971A&nid=2B28CE15-A292-48F7-B88F-5F514F022DBA&type=NewsWire&article=1   (386 words)

  
 [No title]   (Site not responding. Last check: 2007-10-25)
Pliva, s regional leader in the industry, has more than 80 years of tradition behind it.
In the middle of the 1980s, Pliva was in its golden period -- producing drugs, researching new ones and buying other pharmaceutical companies in the former Eastern bloc.
Pliva operates in over 30 countries worldwide and is the leading pharmaceutical company based in Central and Eastern Europe.
www.balkantimes.com /cocoon/setimes/print/en_GB/features/setimes/features/2006/10/17/feature-03   (429 words)

  
 PLIVA d.d. - Company Profile - CBRonline.com
PLIVA is the largest pharmaceutical company headquartered in central Europe.
PLIVA's best selling product is its patented oral antibiotic, azithromycin that it markets in Central and Eastern Europe under the brand name Sumamed.
PLIVA's azithromycin has also been licensed to Pfizer and has been marketed as Zithromax in the US and elsewhere.
www.cbronline.com /companyprofile.asp?guid=99D2FE24-BD90-41CD-B08E-3EBB83CB971A&CType=Background   (170 words)

  
 PLIVA Lachema : MEDIA : Press release
In 1998, PLIVA was the first corporation from the CEE region to gain access to the euro commercial papers market, which is primarily reserved for financing the most prominent players.
In accordance with the changes that PLIVA has gone through in the past five years, it has decided to renew the Programme by adding new issuers, revising dealer panel and increasing flexibility of the programme.
Becoming a member of the Hall of Fame reconfirms that PLIVA is a company that follows global trends and invests continuous efforts in advancing its strategy, goals and organisation.
www.lachema.cz /en/media.php?start=10&days=0&type=p&m=media&   (736 words)

  
 vb.is : Tilkynnt í næstu viku hvaða félag fær að kaupa Pliva   (Site not responding. Last check: 2007-10-25)
Auk Actavis og Barr er talið að nokkrir fjárfestingasjóðir hafi áhuga á að kaupa Pliva.
Pliva hafnaði fyrsta tilboði Actavis, sem hljóðaði upp á HKR570 á hlut, og í kjölfarið hækkaði íslenska fyrirtækið kauptilboðið um 11% í HKR630 á hlut, sem samsvarar um 150 milljörðum á núverandi gengi.
Hagnaður Pliva dróst saman um 32% á fyrsta ársfjórðungi, samanborið við sama tímabili í fyrra, í 30,2 milljónir dollara (2,25 milljarðar íslenskra króna) úr 44,2 milljónum dollara.
www.frettir.is /news_print.php?id=16838   (334 words)

  
 PLIVA Announces Changes in Management and Supervisory Boards
PLIVA's Supervisory Board Appoints Three New Members to Management Board and Calls for Extraordinary General Assembly to Elect New Supervisory Board ZAGREB, Croatia, Oct. 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) and its newly acquired subsidiary PLIVA d.d.
PLIVA's Management Board will continue to be led by Zeljko Covic as President and Chief Operating Officer and Ivan Mijatovic will remain as Member and Chief Financial Officer.
PLIVA and Barr strongly thank each of them for their contribution to the company during the term of their mandate.
www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-31-2006/0004463248&EDATE=   (576 words)

  
 BH Tourism - Pliva Lake Region
The Pliva River Region is located in the north-central part of the Bosnia region of Bosnia and Herzegovina.
Sipovo is located near the source of the Pliva River, Jezero is located near the Pliva Lakes, and Jajce is located where the Pliva River flows into the Vrbas River.
The Pliva River provides the natural connection between the three towns of Jajce, Jezero, and Sipovo.
www.bhtourism.ba /eng/plivariverregion.wbsp   (149 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.